Is NRIX a Buy? What to Consider in 2026
Short answer
The bull case for Nurix Therapeutics (NRIX) rests on Bexobrutideg pivotal path: The lead value driver is bexobrutideg, an oral BTK degrader positioned as potentially best-in-class in relapsed or refractory CLL. Revenue (Q1 FY2026, quarter ended Feb 28 2026) is ~$6.3 million. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: As a clinical-stage biotech, Nurix has no approved product and generates only modest collaboration revenue against large research spending, so it posts substantial net losses and depends on its cash balance and partner payments to keep funding trials. Whether NRIX is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
Nurix Therapeutics is a clinical-stage biopharmaceutical company that designs targeted protein degradation medicines, small molecules that harness the body's own protein-disposal machinery to eliminate disease-driving proteins rather than merely blocking them. Its lead program, bexobrutideg (NX-5948), is an oral, brain-penetrant degrader of BTK being studied in chronic lymphocytic leukemia and other blood cancers, with a pivotal Phase 2 DAYBreak CLL-201 study supporting a potential accelerated approval and a Phase 3 DAYBreak CLL-306 study planned to begin around mid-2026. Beyond bexobrutideg, Nurix has wholly owned programs including zelebrudomide (NX-2127) and the CBL-B inhibitor NX-1607, plus partnered discovery work with Gilead Sciences, Sanofi, and Pfizer where it retains options to co-develop and share profits. The investment picture is that of a platform biotech: Nurix generates only modest collaboration revenue, spends heavily on research, and posts large net losses funded by a sizable cash reserve. In June 2026 it announced a global collaboration with Roche to co-develop and co-commercialize bexobrutideg across hematology, immunology, and neurology, a multi-billion-dollar deal (in potential milestones) that validates the asset and adds non-dilutive funding. As of February 28, 2026 the company held about $540.7 million in cash and marketable securities, and its market capitalization was roughly $1.6 billion. Returns depend on whether the pivotal trials read out positively, whether bexobrutideg reaches the market, and how the partnership milestones convert into cash, all of which remain uncertain.
What's the case for buying NRIX?
1. Bexobrutideg pivotal path.
The lead value driver is bexobrutideg, an oral BTK degrader positioned as potentially best-in-class in relapsed or refractory CLL. The pivotal Phase 2 DAYBreak CLL-201 study is intended to support an accelerated approval, and a confirmatory Phase 3 DAYBreak CLL-306 was slated to start around mid-2026. Positive, durable response data would be the single largest catalyst for the stock.
2. Roche collaboration.
In June 2026 Nurix announced a global collaboration with Roche to co-develop and co-commercialize bexobrutideg across malignant hematology, immunology, and neurology. The deal brings upfront and milestone payments plus shared development costs, validating the asset and extending Nurix's runway with non-dilutive capital while keeping the company exposed to commercial upside.
3. Partnered pipeline and platform.
Nurix earns collaboration revenue and future milestones from partnerships with Gilead Sciences (an IRAK4 degrader), Sanofi (a STAT6 degrader), and Pfizer. These deals help fund the platform and provide multiple shots on goal beyond the wholly owned CLL programs, though the largest partnered payments are contingent on downstream clinical and regulatory progress.
4. Immunology and pipeline expansion.
Beyond oncology, Nurix is pursuing autoimmune and inflammatory uses, including an IND target for a tablet formulation of bexobrutideg in immunology, plus additional degraders like NX-1607. Broadening from cancer into larger autoimmune markets is how the platform could scale, but these programs are earlier and years from potential revenue.
What are the risks to NRIX?
As a clinical-stage biotech, Nurix has no approved product and generates only modest collaboration revenue against large research spending, so it posts substantial net losses and depends on its cash balance and partner payments to keep funding trials. The value is concentrated in bexobrutideg, making the stock highly sensitive to a single set of trial readouts: disappointing efficacy or safety data, a regulatory setback, or a slower-than-expected pivotal path could sharply reduce the valuation. The company competes in a crowded targeted-protein-degradation field against Arvinas, Kymera, C4 Therapeutics, and large pharma, and against established BTK inhibitors already on the market. Future equity raises could dilute shareholders, and milestone payments from Roche, Gilead, Sanofi, and Pfizer are contingent and may never fully materialize. This is a high-risk, high-volatility name unsuitable for investors who need current income or capital preservation.
How is NRIX valued? (as of MARCH 2026)
Snapshot for NRIX as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (Q1 FY2026, quarter ended Feb 28 2026): ~$6.3 million
- Revenue (year-ago quarter): ~$18.5 million
- R&D expense (Q1 FY2026): ~$84.1 million
- Net loss (Q1 FY2026): ~$87.2 million (~-$0.79 per share)
- Cash & marketable securities (Feb 28 2026): ~$540.7 million
- Market cap (mid-2026): ~$1.6 billion
Nurix is pre-profit, so traditional metrics like P/E do not apply; the market values it on pipeline potential, partnership economics, and cash runway. Q1 FY2026 revenue fell sharply year over year as certain Sanofi collaboration research terms wound down, while R&D spending drove a wider net loss. The roughly $540 million cash position funds the registrational bexobrutideg program and broader pipeline, though a quarterly burn near $80 million and future trials mean funding and dilution remain key watch items.
How do you decide if NRIX is a buy?
Rather than asking whether NRIX is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold NRIX indirectly through an index or sector ETF before adding more.
For the full picture, see the NRIX stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about NRIX against your real portfolio and see your actual exposure before deciding.
The bottom line on NRIX
The bottom line: Nurix Therapeutics's story right now is Bexobrutideg pivotal path, with revenue (q1 fy2026, quarter ended feb 28 2026) at ~$6.3 million. If you believe that narrative continues, the call is about sizing NRIX sensibly and checking overlap with what you own; if you doubt it (the risk: as a clinical-stage biotech, Nurix has no approved product and generates only modest collaboration revenue against large research spending, so it posts substantial net losses and depends on its cash balance and partner payments to keep funding trials.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around NRIX with Walnut
Use Nurix Therapeutics as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is NRIX a good stock to buy right now?
+
The case for Nurix Therapeutics right now is Bexobrutideg pivotal path, with revenue (q1 fy2026, quarter ended feb 28 2026) at ~$6.3 million. If you believe that thesis holds, NRIX is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is as a clinical-stage biotech, Nurix has no approved product and generates only modest collaboration revenue against large research spending, so it posts substantial net losses and depends on its cash balance and partner payments to keep funding trials. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does Nurix Therapeutics do?
+
Nurix Therapeutics is a clinical-stage biopharmaceutical company that designs targeted protein degradation medicines, small molecules that harness the body's own protein-disposal m
What are the main risks of NRIX?
+
As a clinical-stage biotech, Nurix has no approved product and generates only modest collaboration revenue against large research spending, so it posts substantial net losses and depends on its cash balance and partner payments to keep funding trials. The value is concentrated in bexobrutideg, making the stock highly sensitive to a single set of trial readouts: disappointing efficacy or safety data, a regulatory setback, or a slower-than-expected pivotal path could sharply reduce the valuation. The company competes in a crowded targeted-protein-degradation field against Arvinas, Kymera, C4 Therapeutics, and large pharma, and against established BTK inhibitors already on the market. Future equity raises could dilute shareholders, and milestone payments from Roche, Gilead, Sanofi, and Pfizer are contingent and may never fully materialize. This is a high-risk, high-volatility name unsuitable for investors who need current income or capital preservation.
What does Nurix Therapeutics do?
+
Nurix is a clinical-stage biopharmaceutical company developing targeted protein degradation medicines, drugs that recruit the cell's natural disposal system to destroy disease-causing proteins. Its focus spans cancer plus autoimmune and inflammatory diseases, led by the oral BTK degrader bexobrutideg.
Is NRIX profitable?
+
No. Nurix is pre-profit and generates only modest collaboration revenue while spending heavily on research. In its Q1 FY2026 quarter (ended February 28, 2026) it reported about $6.3 million in revenue and a net loss of roughly $87.2 million, funded by its cash reserves and partner payments.
What is bexobrutideg?
+
Bexobrutideg (NX-5948) is Nurix's lead drug candidate, an investigational oral, brain-penetrant degrader of BTK. It is being studied in the pivotal Phase 2 DAYBreak CLL-201 trial in relapsed or refractory chronic lymphocytic leukemia, with a Phase 3 confirmatory study planned to begin around mid-2026.
Why did Nurix partner with Roche?
+
In June 2026 Nurix announced a global collaboration with Roche to co-develop and co-commercialize bexobrutideg across hematology, immunology, and neurology. The deal brings upfront and milestone payments plus shared development costs, validating the asset and providing non-dilutive funding while Nurix keeps commercial upside.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell NRIX; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.